Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products, namely, PegIntron ®, Sylatron ®, Macugen ® and CIMZIA ®.
* Enzon does not provide tax advice. Stockholders should consult with their own tax advisors regarding the specific tax treatment of the special dividend that they received from Enzon.
Recent Releases View all »
May 1, 2014
Apr 23, 2013
Dec 17, 2012